Fimasartan, new hypertensive agent, receives marketing approval in Korea

Published: 2010-09-13 07:00:00

Updated: 2010-09-13 07:00:00

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, announced on September 9 that they received marketing approval from the Korean Food and Drug Administration (KFDA) for fimasartan, their new medication for treatment of hypertension. Fimasartan is one of several drugs af...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK